Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a...

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Limited real-world data exist on filgotinib (FILGO) for ulcerative colitis (UC).
• This study evaluates FILGO's effectiveness and safety in a UC patient cohort.

Purpose of the Study:

• To assess the real-world effectiveness and safety of filgotinib in treating ulcerative colitis.
• To identify predictors of clinical remission and response to filgotinib therapy.

Main Methods:

• Retrospective analysis of 102 UC patients treated with FILGO.
• Evaluation of clinical and endoscopic activity using the full Mayo score.
• Primary endpoints included clinical remission, response, mucosal healing, and safety.

Main Results:

• 46.1% achieved clinical remission by study end; 69.6% achieved clinical response.
• First-line FILGO therapy showed higher remission rates (72.2%) compared to second- or third-line (36.8%-41.5%).
• Age >40 and later-line treatment were negative predictors; 60% achieved mucosal healing, and 82.6% had steroid-free remission.

Conclusions:

• Filgotinib demonstrates safety and efficacy in real-world UC treatment.
• Early use of FILGO as a first-line therapy is associated with improved outcomes.
• FILGO is a viable option for UC management, with manageable adverse events.